What Is MOTS-c? The Molecule and the Vial

The published efficacy work is animal and cell work. Reported effects on glucose handling and insulin sensitivity come from studies in mice and from experiments in cultured cells, where amounts are stated per kilogram of animal body weight under a defined route and model. That is the whole of the record that has produced results.

No human trial of MOTS-c is registered. The registry does contain a record that looks like one, and it is worth naming because the resemblance is good. NCT07505745 is listed as a Phase 2 study of MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity, with an enrolment of 120 and a status of recruiting. Its lead sponsor, Hudson Biotech, holds eight such records posted between February and April 2026, one each for BPC-157, Melanotan II, GHK-Cu, retatrutide, tesamorelin, tirzepatide, TB-500 and this compound, every one of them recruiting at a single site. That is a list of products, not a research programme. NCT07487363, the TB-500 entry, states in its own brief summary that it is a fictional example of a ClinicalTrials.gov-style record.

The general lesson outlives this compound. An NCT number is a registration, not a result and not a review: the registry publishes what a sponsor submits and does not check it. Confirming that an identifier resolves proves only that a submission was accepted. The two fields that settle the question are the lead sponsor and the brief summary, and reading them takes about a minute.

The rest of that search is the ordinary kind of noise. The extra results match the search text somewhere in a study description and have nothing to do with this peptide, so the hit count is wrong twice over: most of it is unrelated, and the part that is not is a fabrication. What remains is the animal and cell literature, which is real, and whose founding paper is Lee and colleagues in Cell Metabolism, 2015, PMID 25738459.

The vial arrives with a labelled dry mass, commonly 5 mg or 10 mg. Nothing in it corresponds to a volume until bacteriostatic water goes in, and how much goes in is a free choice.

Concentration is the labelled mass divided by the added volume. A 10 mg vial with 2 mL gives 10 divided by 2, which is 5 mg per mL.

The mass in a draw is concentration multiplied by volume drawn. A U-100 insulin syringe fills 1 mL at 100 units, so one unit is 0.01 mL and 10 units are 0.1 mL. At 5 mg per mL, that draw holds 5 times 0.1, or 0.5 mg, which is 500 mcg.

Change the fill volume and everything after it moves. The same vial in 1 mL gives 10 mg per mL, so 10 units hold 1000 mcg. The same vial in 5 mL gives 2 mg per mL, so 10 units hold 200 mcg. One powder, one label, a fivefold spread in what an identical syringe reading means. That spread is the single most useful thing to understand about buying peptides by mass and dosing them by volume.

The conversions above are exact, and they rest on three inputs that are not.

The first is the label. A stated 10 mg is a claim by a seller about a batch. Independent assay is the only thing that connects a printed number to a measured one, and a compound sold as a research chemical carries no regulatory requirement that they agree.

The second is the syringe scale. Every unit conversion here assumes a U-100 barrel. On a U-40 barrel one unit is 0.025 mL, so the same reading is two and a half times the volume. Nothing about the filled syringe reveals which one is in hand.

The third is that the material survived. Concentration is computed once, at reconstitution, and then quoted for as long as the vial is in use. Peptide in solution is less stable than sealed powder, and no arithmetic tracks the decline, because nobody measured it.

Sellers describe the same kind of product in at least two ways, and the two do not line up without a conversion.

Some list a mass: a 10 mg vial. That is the honest form, because mass is the property the vial actually has. Others list a concentration, quoting something like 5 mg per mL, which is not a property of the vial at all until a fill volume is named. A concentration without a volume is an unfinished statement, and it usually means the seller has assumed a reconstitution the buyer has not agreed to.

Price comparisons need the same normalising. Using assumed figures, a single 10 mg vial at 90 currency units is 90 divided by 10, or 9 per mg. Two 5 mg vials at 55 each come to 110 for the same 10 mg, which is 11 per mg. The second option costs more per mg and less per transaction, and it also splits the material across two seals, which is a stability advantage rather than a pricing one.

There is no marketing authorisation from the FDA, the EMA or the MHRA, or from any other regulator. The compound is not an approved medicine anywhere, and it is sold under research chemical terms.

The practical consequences are concrete rather than abstract. There is no approved product label, so no authority has reviewed a stated amount. There is no summary of product characteristics, so there is no reviewed list of adverse effects. There is no manufacturing standard enforced against the vendor, so the powder's identity and purity are between the buyer and whatever documentation the seller chooses to publish.

An encyclopaedia entry can stop at the molecule. Anyone holding a vial cannot, because the questions that follow are all about the object.

Cost per mg is price divided by labelled mass, so a 10 mg vial at 90 currency units is 9 per mg, on an assumed price since no seller is named here. That figure ranks vials only within a set whose labels have been independently checked, since it divides by a claim.

Vial longevity is labelled mass divided by the mass in each withdrawal. Ten milligrams drawn 500 mcg at a time is 10 divided by 0.5, which is 20 withdrawals, at any fill volume, because dilution changes the reading and not the mass. Every one of those numbers comes from the vial half of the answer, and none of them comes from the biology.